This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
At week 40, mean HbA1c change was -2.40% with 10 mg tirzepatide vs -0.86% with placebo (P < .001).
Why it matters
These results indicate that tirzepatide can be an effective addition to insulin therapy for better blood sugar control in type 2 diabetes. This could lead to improved patient outcomes and management strategies.
How the study worked
A randomized phase 3 clinical trial with 475 participants, comparing tirzepatide doses to placebo over 40 weeks.
What this study cannot tell us
The study was limited to a specific population and duration, and long-term effects of tirzepatide remain to be evaluated.
Read the original research
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
JAMA, 327(6), 534-545
Citation
Dahl, Dominik; Onishi, Yukiko; Norwood, Paul; Huh, Ruth; Bray, Ross; Patel, Hiren; Rodríguez, Ángel. (2022). Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.. JAMA, 327(6), 534-545. https://doi.org/10.1001/jama.2022.0078